Volume 10, Issue 3 ( September 2018 2018)
Iranian Journal of Blood and Cancer 2018, 10(3): 87-91 |
Back to browse issues page
1- Assistant Professor, Department of Hematology-Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Student Research Committee, School of medicine, Isfahan University of Medical sciences, Isfahan, Iran , armansourani@yahoo.com
2- Student Research Committee, School of medicine, Isfahan University of Medical sciences, Isfahan, Iran , armansourani@yahoo.com
Abstract: (3981 Views)
Background: Rituximab can induce a durable remission in plasma exchange refractory thrombotic thrombocytopenic purpura (TTP). Timing of Rituximab infusion in combination with plasma exchange (PE) and long term follow-up for probable side effects of such treatment is still lacking.
Methods: This study was conducted among 10 patients with plasma exchange refractory TTP. According to the study designation, first PE was performed within 36-48 hours after first dose of rituximab.
Results: Eight of ten (80%) patients received 1 course of rituximab. Two of ten (20%) patients received another course of rituximab due to relapse. Repsonse rate (RR) to rituximab in combination with plasma exchange, was 90%. Overall Survival of the patients was 90% and 1 and 5-year relapse free survival rate (RFS) was 90% and 83%, respectively. One of the patients expired due to Systemic Lupus Erythematosus flare up.
Conclusion: According to this study, treatment of refractory TTP with rituximab in combination with PE could be effective.
Iranian Registry of Clinical Trials: IRCT2017012232125N1
Methods: This study was conducted among 10 patients with plasma exchange refractory TTP. According to the study designation, first PE was performed within 36-48 hours after first dose of rituximab.
Results: Eight of ten (80%) patients received 1 course of rituximab. Two of ten (20%) patients received another course of rituximab due to relapse. Repsonse rate (RR) to rituximab in combination with plasma exchange, was 90%. Overall Survival of the patients was 90% and 1 and 5-year relapse free survival rate (RFS) was 90% and 83%, respectively. One of the patients expired due to Systemic Lupus Erythematosus flare up.
Conclusion: According to this study, treatment of refractory TTP with rituximab in combination with PE could be effective.
Iranian Registry of Clinical Trials: IRCT2017012232125N1
: Original Article |
Subject:
Adults Hematology & Oncology
Received: 2018/04/16 | Accepted: 2018/10/24 | Published: 2018/10/24
Received: 2018/04/16 | Accepted: 2018/10/24 | Published: 2018/10/24
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |